Biocryst Pharmaceuticals reported $343K in Cost of Sales for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Adamas Pharmaceuticals ADMS:US 527K 142K
Alexion Pharmaceuticals ALXN:US $ 125.4M 26.8M
Alnylam Pharmaceuticals ALNY:US $ 30.26M 7.23M
Biocryst Pharmaceuticals BCRX:US $ 0.34M 5.54M
Chugai Pharma 4519:JP Y 68059M 12721M
Daiichi Sankyo 4568:JP Y 85152M 3275M
Gilead Sciences GILD:US $ 1390M 29M
GlaxoSmithKline GSK:LN 2519M 108M
Glaxosmithkline GSK:US $ 2519M 108M
Intra Cellular Therapies ITCI:US $ 2.04M 0.58M
IONIS PHARMACEUT IONS:US $ 2.96M 0.38M
Karyopharm Therapeutics KPTI:US $ 1.14M 205K
Neurocrine Biosciences NBIX:US $ 3.1M 0.2M
Ptc Therapeutics PTCT:US $ 7.36M 1.75M
Regeneron Pharmaceuticals REGN:US $ 693.7M 385.7M
Sarepta Therapeutics SRPT:US $ 19.52M 2.83M
Ultragenyx Pharmaceutical RARE:US $ 3.14M 2.05M
Vertex Pharmaceuticals VRTX:US $ 227.97M 35.64M
YTE INCY:US $ 32.63M 8.81M
Zogenix ZGNX:US $ 1.22M 0.55M